SPORE in Brain Cancer

$2,067,370P50FY2014CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications & trials

Paper 39622255 Paper 39582234 Paper 39508297 Paper 39285933 Paper 39253988 Paper 39195544 Paper 39184873 Paper 39148489 Paper 39137729 Paper 38894960 Paper 38823209 Paper 38681802 Paper 38668378 Paper 38617333 Paper 38596290 Paper 38311852 Paper 38256021 Paper 38201290 Paper 38183103 Paper 38168332 Paper 38014161 Paper 37932451 Paper 37847405 Paper 37722850 Paper 37721513 Paper 37603323 Paper 37587333 Paper 37548050 Paper 37540752 Paper 37379361 Paper 37313712 Paper 37261908 Paper 37252969 Paper 37243720 Paper 37214825 Paper 37188783 Paper 37104131 Paper 37057598 Paper 36960827 Paper 36807110 Paper 36727622 Paper 36648331 Paper 36541756 Paper 36167417 Paper 36139163 Paper 36082440 Paper 35879429 Paper 35868246 Paper 35851545 Paper 35816267 Paper 35702422 Paper 35649412 Paper 35597788 Paper 35498876 Paper 35418578 Paper 35393952 Paper 35294699 Paper 35217866 Paper 35152274 Paper 35098585 Paper 34965971 Paper 34723252 Paper 34685601 Paper 34453686 Paper 34437714 Paper 34249223 Paper 34244484 Paper 34138753 Paper 34059921 Paper 34039636 Paper 33988982 Paper 33959279 Paper 33795384 Paper 33793044 Paper 33743008 Paper 33711459 Paper 33595664 Paper 33439726 Paper 33438761 Paper 33294266 Paper 33231254 Paper 33230295 Paper 33223031 Paper 33042135 Paper 33040087 Paper 33031376 Paper 33020667 Paper 32854207 Paper 32847614 Paper 32721947 Paper 32605912 Paper 32587392 Paper 32554515 Paper 32540905 Paper 32536592 Paper 32236410 Paper 32166329 Paper 31766580 Paper 31455679 Paper 30926639

Abstract

This MD Anderson Brain Cancer SPORE renewal application builds upon the significant progress achieved in the initial funding period, including the development of novel biological (oncolytic virus, stem cells), targeted (PI3K inhibitors), and immunomodulaton (p-STAT-3 inhibition) therapeutic strategies; as well as the development of biomarkers that inform personalized care of GBM patients. In this renewal, our goal is to capitalize on these prior successes in order to dramatically improve the survival of patients with malignant gliomas. We have established a multidisciplinary, integrated, flexible, and highly translational (bench to bedside and back) research program that aims to discover and rationally test new biologic, targeted, and immunological therapies, and that seeks to develop prognostic and predictive biomarkers that inform individualized approaches to GBM treatment. To achieve our goals we propose four fully translational research projects (3 therapeutic; 1 population-based), all of which incorporate tissue-based clinical trials, and are supported by five Cores: Administrative (A), Pathology and Biorepository (B), Biostatics and Bioinformatics (C), Clinical (D), and Animal (E). The Developmental Research Program (DRP) and Career Development Program (CDP) continue as successful aspects of our SPORE as they encourage novel studies and promote young investigators. The aims of the four projects are to: Project 1: Enhance the efficacy of a novel oncolytic adenovirus, Delta-24-RGD, by combining it with temozolomide, by exploiting autophagy, and by improving delivery using bone marrow stem cells; Project 2: Explore combinatorial targeted strategies based on PISKinase inhibition by elucidating mechanisms of single-drug escape in a large collection of patient-derived glioma stem cells and tumor specimens; Project 3: Validate in phase III trials a new robust GBM prognostic classifier, the molecular-clinical prognosticator (MCP), and develop clinical diagnostics that predict response to bevacizumab an ipilimumab; Project 4: Modulate GBM induced immunosuppression using a novel p-STAT-3 inhibitor, WP1066. Through this research program and with the full support of The University of Texas M.D. Anderson Cancer Center, this SPORE will make a significant impact toward the diagnosis and treatment of patients with malignant brain tumors.

View original record on NIH RePORTER →